电子提醒、经济激励与社会支持对心肌梗死后结局的影响:HeartStrong随机临床试验
该两臂随机临床试验纳入1509例18至80岁、出院主要诊断为AMI且正在使用至少2种研究药物(他汀、阿司匹林、β受体阻滞剂、抗血小板药)的患者,按2:1随机分为复合干预组(电子药瓶+抽奖激励+社会支持,1003例)与常规护理组(506例),干预12个月。主要终点首次血管事件再住院或死亡无统计学显著差异(HR 1.04;95%CI 0.71-1.52;P=.84);全因再住院、重复住院次数、服药依从性及12个月医疗费用均无统计学显著差异。结论认为该复合干预未显著改善AMI幸存者的服药依从性或血管再住院结局。
要点
- 主要终点首次血管事件再住院或死亡:干预组与常规护理组无统计学显著差异(HR 1.04;95%CI 0.71-1.52;P=.84)。
- 首次全因再住院无统计学显著差异(HR 0.89;95%CI 0.73-1.09;P=.27),重复住院次数亦无统计学显著差异(HR 0.94;95%CI 0.60-1.48;P=.79)。
- 平均服药依从性常规护理组0.42(SD 0.39) vs 干预组0.46(SD 0.39),差值0.04(95%CI -0.01至0.09;P=.10),无统计学显著差异。
- 12个月医疗费用常规护理组29811美元(SD 74850) vs 干预组24038美元(SD 66915),差值-5773美元(95%CI -13682至2137;P=.15),无统计学显著差异。
- 受试者平均(SD)年龄61.0(10.3)岁,女性占35.5%(n=536)。
适用人群与场景
- 18至80岁、因AMI住院1至180天且出院回家、出院主要诊断为AMI、当前处方至少2种研究药物(他汀、阿司匹林、β受体阻滞剂、抗血小板药)的AMI幸存者。
- 招募自7179例 contacted AMI幸存者中的1509例,投保于5家美国大型保险公司或宾夕法尼亚大学健康系统的Medicare按服务付费项目。
处置流程与药物剂量
- 干预组(1003例)接受电子药瓶联合抽奖激励与社会支持以促进服药依从性,干预持续12个月。
- 对照组(506例)接受常规护理。
研究设计与关键结果
- 研究设计:两臂随机临床试验,2013年至2016年进行,12个月干预;研究者对分组设盲,参与者未设盲;采用健康计划介导的干预。
- 样本量1509例,随机2:1分为干预组1003例与常规护理组506例。
- 主要终点首次血管事件再住院或死亡:HR 1.04(95%CI 0.71-1.52;P=.84),无统计学显著差异。
- 首次全因再住院:HR 0.89(95%CI 0.73-1.09;P=.27),无统计学显著差异;重复住院总数:HR 0.94(95%CI 0.60-1.48;P=.79),无统计学显著差异。
- 平均(SD)服药依从性:常规护理组0.42(0.39) vs 干预组0.46(0.39),差值0.04(95%CI -0.01至0.09;P=.10),无统计学显著差异。
- 12个月平均(SD)医疗费用:常规护理组29811美元(74850) vs 干预组24038美元(66915),差值-5773美元(95%CI -13682至2137;P=.15),无统计学显著差异。
- 女性占35.5%(n=536);平均(SD)年龄61.0(10.3)岁。
证据类型、等级与局限
- 证据类型:随机临床试验(两臂,2:1随机分组)。
- 试验注册号:clinicaltrials.gov NCT01800201。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该复合干预(电子药瓶+抽奖激励+社会支持)未显著改善AMI幸存者的服药依从性或血管再住院结局,作者结论不支持将其作为改善上述结局的有效措施。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Adherence to medications prescribed after acute myocardial infarction (AMI) is low. Wireless technology and behavioral economic approaches have shown promise in improving health behaviors.
OBJECTIVE: To determine whether a system of medication reminders using financial incentives and social support delays subsequent vascular events in patients following AMI compared with usual care.
DESIGN, SETTING, AND PARTICIPANTS: Two-arm, randomized clinical trial with a 12-month intervention conducted from 2013 through 2016. Investigators were blinded to study group, but participants were not. Design was a health plan-intermediated intervention for members of several health plans. We recruited 1509 participants from 7179 contacted AMI survivors (insured with 5 large US insurers nationally or with Medicare fee-for-service at the University of Pennsylvania Health System). Patients aged 18 to 80 years were eligible if currently prescribed at least 2 of 4 study medications (statin, aspirin, β-blocker, antiplatelet agent), and were hospital inpatients for 1 to 180 days and discharged home with a principal diagnosis of AMI.
INTERVENTIONS: Patients were randomized 2:1 to an intervention using electronic pill bottles combined with lottery incentives and social support for medication adherence (1003 patients), or to usual care (506 patients).
MAIN OUTCOMES AND MEASURES: Primary outcome was time to first vascular rehospitalization or death. Secondary outcomes were time to first all-cause rehospitalization, total number of repeated hospitalizations, medication adherence, and total medical costs.
RESULTS: A total of 35.5% of participants were female (n = 536); mean (SD) age was 61.0 (10.3) years. There were no statistically significant differences between study arms in time to first rehospitalization for a vascular event or death (hazard ratio, 1.04; 95% CI, 0.71 to 1.52; P = .84), time to first all-cause rehospitalization (hazard ratio, 0.89; 95% CI, 0.73 to 1.09; P = .27), or total number of repeated hospitalizations (hazard ratio, 0.94; 95% CI, 0.60 to 1.48; P = .79). Mean (SD) medication adherence did not differ between control (0.42 [0.39]) and intervention (0.46 [0.39]) (difference, 0.04; 95% CI, -0.01 to 0.09; P = .10). Mean (SD) medical costs in 12 months following enrollment did not differ between control ($29 811 [$74 850]) and intervention ($24 038 [$66 915]) (difference, -$5773; 95% CI, -$13 682 to $2137; P = .15).
CONCLUSIONS AND RELEVANCE: A compound intervention integrating wireless pill bottles, lottery-based incentives, and social support did not significantly improve medication adherence or vascular readmission outcomes for AMI survivors.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01800201.
参考来源
- Volpp KG, Troxel AB, Mehta SJ, et al. Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial. JAMA Intern Med. 2017. PMID: 28654972. doi:10.1001/jamainternmed.2017.2449
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。